• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Are we progressing in prostate cancer management?我们在前列腺癌治疗方面取得进展了吗？
Asian J Urol. 2021 Apr;8(2):241-242. doi: 10.1016/j.ajur.2020.09.001. Epub 2020 Sep 11.
2
iTRAQ identification of candidate serum biomarkers associated with metastatic progression of human prostate cancer.iTRAQ 鉴定与人类前列腺癌转移进展相关的候选血清生物标志物。
PLoS One. 2012;7(2):e30885. doi: 10.1371/journal.pone.0030885. Epub 2012 Feb 15.
3
Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial.醋酸阿比特龙治疗化疗后进展的转移性去势抵抗性前列腺癌患者：多中心、开放标签、早期准入方案试验的最终分析。
Lancet Oncol. 2014 Oct;15(11):1263-8. doi: 10.1016/S1470-2045(14)70417-6. Epub 2014 Sep 18.
4
Targeting FSH in androgen-independent prostate cancer: abarelix for prostate cancer progressing after orchiectomy.针对雄激素非依赖性前列腺癌的促卵泡激素（FSH）：阿巴瑞克用于睾丸切除术后进展的前列腺癌
Urology. 2004 Feb;63(2):342-7. doi: 10.1016/j.urology.2003.09.045.
5
[Vaquez disease, symptomatic of a slowly progressing cancer of the prostate with osseous metastases; cure of the polycythemia by hormonal treatment of the cancer].[真性红细胞增多症，为伴有骨转移的前列腺缓慢进展性癌的症状；通过癌症的激素治疗治愈红细胞增多症]
Lyon Med. 1950 Jun 25;183(26):432-5.
6
Isolated peritoneal carcinomatosis in prostate cancer: from a successful hormonal management to a review of the literature.前列腺癌孤立性腹膜癌转移：从成功的激素治疗到文献综述
Future Sci OA. 2021 Apr 30;7(6):FSO707. doi: 10.2144/fsoa-2021-0009.
7
Sequential maximum androgen blockade (MAB) in minimally symptomatic prostate cancer progressing after initial MAB: two case reports.初始雄激素阻断治疗（MAB）后病情进展的轻度症状性前列腺癌患者的序贯最大雄激素阻断治疗（MAB）：两例病例报告
Cancer Biol Med. 2014 Dec;11(4):277-80. doi: 10.7497/j.issn.2095-3941.2014.04.007.
8
Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents.卡巴他赛在多西他赛和新一代内分泌治疗药物治疗后进展的去势抵抗性前列腺癌中的活性。
Eur Urol. 2014 Sep;66(3):459-65. doi: 10.1016/j.eururo.2013.11.044. Epub 2013 Dec 17.
9
Overall survival with [Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial.LuLu-PSMA-617 对比卡巴他赛用于转移性去势抵抗性前列腺癌（TheraP）的总生存期：一项随机、开放标签、2 期临床试验的次要结局。
Lancet Oncol. 2024 Jan;25(1):99-107. doi: 10.1016/S1470-2045(23)00529-6. Epub 2023 Nov 30.
10
Combination chemotherapy following adrenal suppression in androgen- independent prostate cancer.雄激素非依赖性前列腺癌肾上腺抑制后的联合化疗。
Eur Urol. 2000 Sep;38(3):255-8. doi: 10.1159/000020290.

本文引用的文献

1
Oncological outcomes of patients with ductal adenocarcinoma of the prostate receiving radical prostatectomy or radiotherapy.接受根治性前列腺切除术或放射治疗的前列腺导管腺癌患者的肿瘤学结局。
Asian J Urol. 2021 Apr;8(2):227-234. doi: 10.1016/j.ajur.2020.05.005. Epub 2020 May 23.
2
Knowing what's growing: Why ductal and intraductal prostate cancer matter.了解正在发生的情况：为什么导管内和导管前列腺癌至关重要。
Sci Transl Med. 2020 Mar 4;12(533). doi: 10.1126/scitranslmed.aaz0152.
3
Features and Prognostic Significance of Intraductal Carcinoma of the Prostate.前列腺导管内癌的特征和预后意义。
Eur Urol Oncol. 2018 May;1(1):21-28. doi: 10.1016/j.euo.2018.03.013. Epub 2018 May 15.
4
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.全球癌症统计数据 2018：GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
5
The impact of intraductal carcinoma of the prostate on the site and timing of recurrence and cancer-specific survival.前列腺导管内癌对复发部位、时间及癌症特异性生存的影响。
Prostate. 2018 Jul;78(10):697-706. doi: 10.1002/pros.23513. Epub 2018 Mar 30.
6
Clinical implications of PTEN loss in prostate cancer.PTEN 缺失在前列腺癌中的临床意义。
Nat Rev Urol. 2018 Apr;15(4):222-234. doi: 10.1038/nrurol.2018.9. Epub 2018 Feb 20.
7
Integrative Genomic Analysis of Coincident Cancer Foci Implicates CTNNB1 and PTEN Alterations in Ductal Prostate Cancer.整合基因组分析偶发癌灶提示 CTNNB1 和 PTEN 改变与前列腺导管癌相关。
Eur Urol Focus. 2019 May;5(3):433-442. doi: 10.1016/j.euf.2017.12.003. Epub 2017 Dec 8.
8
Prognostic values of clinicopathological characteristics and survival outcomes in prostate infiltrating ductal carcinoma: a population-based study.前列腺浸润性导管癌临床病理特征及生存结局的预后价值：一项基于人群的研究。
Oncotarget. 2017 Apr 25;8(17):29048-29055. doi: 10.18632/oncotarget.16070.
9
Incidence and outcomes of ductal carcinoma of the prostate in the USA: analysis of data from the Surveillance, Epidemiology, and End Results program.美国前列腺导管癌的发病率和结局：监测、流行病学和最终结果计划的数据分析。
BJU Int. 2012 Mar;109(6):831-4. doi: 10.1111/j.1464-410X.2011.10520.x. Epub 2011 Aug 24.

Are we progressing in prostate cancer management?

作者信息

Patel Hiten Rh, Patel Reena

机构信息

Department of Urology, University of Rochester Medical & Dental School, NY, USA.

St George's University of London Medical School, London, United Kingdom.

出版信息

Asian J Urol. 2021 Apr;8(2):241-242. doi: 10.1016/j.ajur.2020.09.001. Epub 2020 Sep 11.

DOI:10.1016/j.ajur.2020.09.001
PMID:33996484
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8099682/
Abstract
摘要